
CATE is an engineered, non-pathogenic *E. coli* strain that colonizes and kills tumors. Two built-in safety checkpoints combine molecular tumor-targeting and external control in a cancer treatment.

EIHZURICH

Vasileios Cheras, Nicolas Huber, Anubhav Jain, Nikolaos Korasidis, David Schweingruber, Valentin Senlis, Irma Telarovic, Lida Vadakumchery



References

Stritzker, Jochen, et al. "Tumor-specific colonization, tissue distribution, and gene induction by probiotic Escherichia coli Nissle 1917 in live mice." International journal of medical microbiology 297.3 (2007): 151-162.

Hill, Philip J., et al. "Magnetic resonance imaging of tumors colonized with bacterial ferritin-expressing Escherichia coli." PLoS One 6.10 (2011): e25409. Piraner, Dan I., et al. "Tunable thermal bioswitches for in vivo control of microbial therapeutics." Nature chemical biology

13.1 (2017): 75-80. Yamada, Tohru, et al. "Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer." Procee-

dings of the National Academy of Sciences 99.22 (2002): 14098-14103. Bernardes, Nuno, Ananda M. Chakrabarty, and Arsenio M. Fialho. "Engineering of bacterial strains and their products for

cancer therapy." Applied microbiology and biotechnology 97.12 (2013): 5189-5199.





stic to have enough sensitivity [to image CATE] venously would not be an exclusion criterion, if it has passed all the required pre-clinical tests, of course."



ETH Zürich,

Switzerland

Interviews

Dr. Simon Ittig

CEO T3 Pharma

"I do believe that the technology [bacterial cancer

therapy] is well advanced and robust. We have a lot

of data to demonstrate this and it inspires confidence

in people."

Prof. Dr. Markus Rudin

Institute of Biomedical Engineering,

ETH Zurich

"Based on the numbers you've presented it's reali-

with MRI7."

Dr. med. Christian Britschgi

Oncologist,

University Hospital Zurich

"The fact that you would use bacteria intra-



Talks

NTU Athens,

Greece